このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

インヒビターを含まない血友病 A の出生から 12 か月齢までの参加者における皮下エミシズマブの有効性、安全性、薬物動態、および薬力学を評価するための研究 (HAVEN 7)

2026年9月30日 更新者:Hoffmann-La Roche

インヒビターを含まない血友病 A の出生時から 12 か月齢までの患者における皮下エミシズマブの有効性、安全性、薬物動態、および薬力学を評価する第 IIIb 相、多施設、非盲検、単群試験

This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to ≤12 months of age with severe hemophilia A (intrinsic factor VIII [FVIII] level <1%) without FVIII inhibitors. The study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 milligrams per kilogram of body weight (mg/kg) once every 2 weeks (Q2W) for 52 weeks. After 1 year of treatment, participants will continue to receive emicizumab (1.5 mg/kg once every week [QW], 3 mg/kg Q2W or 6 mg/kg once every 4 weeks [Q4W]) over a 7-year long-term follow-up period under this study frame.

調査の概要

状態

積極的、募集していない

条件

介入・治療

研究の種類

介入

入学 (実際)

55

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Arizona
      • Phoenix、Arizona、アメリカ、85016
        • Phoenix Children's Hospital
    • California
      • Los Angeles、California、アメリカ、90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora、Colorado、アメリカ、80045
        • University of Colorado Denver, Children's Hospital
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70112
        • Tulane University Health Sciences Center
    • Michigan
      • Ann Arbor、Michigan、アメリカ、48109-0934
        • University of Michigan
    • Washington
      • Seattle、Washington、アメリカ、98105
        • Seattle Children's Hospital
      • Glasgow、イギリス、G51 4TF
        • Queen Elizabeth University Hospital
      • Tel HaShomer、イスラエル、5262100
        • Sheba Medical Center - National Hemophilia Center
    • Campania
      • Naples、Campania、イタリア、80123
        • AORN Santobono Pausilipon
    • Emilia-Romagna
      • Parma、Emilia-Romagna、イタリア、43126
        • AOU di Parma
    • Lombardy
      • Milan、Lombardy、イタリア、20122
        • IRCCS Ca' Granda Ospedale Maggiore Policlinico
    • Tuscany
      • Florence、Tuscany、イタリア、50134
        • AOU Careggi
    • New South Wales
      • Westmead、New South Wales、オーストラリア、2145
        • The Children's Hospital at Westmead
    • Victoria
      • Parkville、Victoria、オーストラリア、3052
        • Royal Children's Hospital
    • Western Australia
      • Nedlands、Western Australia、オーストラリア、6009
        • Perth Children's Hospital
      • Vienna、オーストリア、1090
        • Medizinische Universität Wien
    • Ontario
      • Ottawa、Ontario、カナダ、K1H 8L1
        • Children's Hospital of Eastern Ontario
      • Toronto、Ontario、カナダ、M5G 1X8
        • The Hospital for Sick Children
      • Madrid、スペイン、28046
        • Hospital Universitario la Paz
      • Seville、スペイン、41013
        • Hospital Universitario Virgen del Rocio
    • Barcelona
      • Esplugues de Llobregat、Barcelona、スペイン、08950
        • Hospital Sant Joan de Deu
      • Adana、トルコ(Türkiye)、01130
        • Adana Acibadem Hospital
      • Ankara、トルコ(Türkiye)、06100
        • Hacettepe University Medical Faculty
      • Izmir、トルコ(Türkiye)、35100
        • Ege University, School of Medicine
      • Samsun、トルコ(Türkiye)、55139
        • Ondokuz Mayis Univ. Med. Fac.
      • Bonn、ドイツ、53127
        • Universitätsklinikum Bonn
      • Mörfelden-Walldorf、ドイツ、64546
        • Hämophilie-Zentrum Rhein Main GmbH
      • Paris、フランス、75015
        • Groupe Hospitalier Necker Enfants Malades
    • São Paulo
      • Ribeirão Preto、São Paulo、ブラジル、14051-140
        • Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
      • Brussels、ベルギー、1200
        • Cliniques Universitaires St-Luc
      • Leuven、ベルギー、3000
        • UZ Leuven Gasthuisberg
      • Johannesburg、南アフリカ、2193
        • Charlotte Maxeke Johannesburg Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

1秒~1年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age from birth to ≤12 months at time of informed consent
  • Body weight ≥3 kilograms (kg) at time of informed consent. Patients with a lower body weight can be enrolled after they have reached a body weight of 3 kg. Premature babies (gestational age <38 weeks) may be enrolled as long as they have reached a body weight of 3 kg. For premature babies, the corrected gestational age should be reported.
  • Mandatory receipt of vitamin K prophylaxis according to local standard practice
  • Diagnosis of severe congenital hemophilia A (intrinsic FVIII level <1%)
  • A negative test for FVIII inhibitor (i.e., <0.6 Bethesda units [BU]/mL) locally assessed during the 2-week screening period
  • No history of documented FVIII inhibitor (i.e., <0.6 BU/mL), FVIII drug-elimination half-life <6 hours, or FVIII recovery <66%
  • Previously untreated patients or minimally treated patients (i.e., up to 5 days of exposure with hemophilia-related treatments, such as plasma-derived FVIII, recombinant FVIII, fresh frozen plasma, cryoprecipitate, or whole blood products)
  • Documentation of the details of the hemophilia-related treatments received since birth
  • Documentation of the details of the bleeding episodes since birth
  • For patients from birth to <3 months of age at the time of study entry: no evidence of active intracranial hemorrhage, as confirmed by a negative cranial ultrasound at screening irrespective of delivery mode
  • Adequate hematologic, hepatic, and renal function, as defined in the protocol
  • For parents/caregivers: willingness and ability to comply with the study protocol requirements, scheduled visits, treatment plans, laboratory tests, completion of applicable questionnaires, and other study procedures

Exclusion Criteria:

  • Inherited or acquired bleeding disorder other than severe hemophilia A
  • Use of systemic immunomodulators (e.g., interferon) at enrollment or planned use during the study
  • Receipt of any of the following: Prior use of emicizumab prophylaxis including investigational or commercial emicizumab; An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 drug-elimination half-lives of last drug administration; A non-hemophilia-related investigational drug within the last 30 days or 5 drug-elimination half-lives, whichever is shorter; An investigational drug concurrently
  • Current active severe bleed, such as intracranial hemorrhage
  • Planned surgery (excluding minor procedures, e.g., circumcision, CVAD placement) during the study
  • History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
  • Patients who are at high risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA, such as thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome) in the investigator's judgment
  • Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis in patients for whom anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
  • Any hereditary or acquired maternal condition that may predispose the patient to thrombotic events (e.g., inherited thrombophilias antiphospholipid syndrome)
  • Other diseases (e.g., certain autoimmune diseases) that may increase risk of bleeding or thrombosis
  • Known infection with HIV, hepatitis B virus, or hepatitis C virus
  • Serious infection requiring antibiotics or antiviral treatments within 14 days prior to screening
  • Concurrent disease, treatment, abnormality in clinical laboratory tests, vital signs measurements, or physical examination findings that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the patient's safe participation in and completion of the study or interpretation of the study results
  • Unwillingness of the parent or caregiver to allow receipt of blood or blood products, or any standard-of-care treatment for a life-threatening condition
  • Any other medical, social, or other condition that may prevent adequate compliance with the study protocol in the opinion of the investigator

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:エミシズマブ

Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.

At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.

During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first.

他の名前:
  • ヘムライブラ
  • RO5534262
  • RG6013
  • ACE910

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Model-Based Annualized Bleeding Rate for Treated Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for All Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for All Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for All Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for Treated Joint Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds
時間枠:From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

二次結果の測定

結果測定
メジャーの説明
時間枠
エミシズマブの血漿トラフ濃度 (Ctrough)
時間枠:1、3、5、7、9、13、17、21、25、29、33、37、41、45、49、および 53 週に事前投与
1、3、5、7、9、13、17、21、25、29、33、37、41、45、49、および 53 週に事前投与
抗エミシズマブ抗体の発生率
時間枠:1、5、17、29、41、および 53 週後、臨床的に必要な場合は試験完了まで (最長 8 年間)
1、5、17、29、41、および 53 週後、臨床的に必要な場合は試験完了まで (最長 8 年間)
長期追跡期間中の特定の時点での血友病関節健康スコア (HJHS) 合計スコア
時間枠:追跡調査4年目、5年目、6年目、7年目、8年目
追跡調査4年目、5年目、6年目、7年目、8年目
長期追跡期間中の特定の時点での特定の関節の磁気共鳴画像法 (MRI) スコア
時間枠:追跡調査5年目と8年目
追跡調査5年目と8年目
有害事象の発生率と重症度(重症度は世界保健機関(WHO)の毒性等級スケールに従って決定)
時間枠:エミシズマブの初回投与から研究完了まで(8年間)
エミシズマブの初回投与から研究完了まで(8年間)
血栓塞栓性イベントの発生率
時間枠:エミシズマブの初回投与から研究完了まで(8年間)
エミシズマブの初回投与から研究完了まで(8年間)
血栓性微小血管症の発生率
時間枠:エミシズマブの初回投与から研究完了まで(8年間)
エミシズマブの初回投与から研究完了まで(8年間)
注射部位反応の発生率と重症度(重症度はWHOの毒性等級スケールに従って決定)
時間枠:エミシズマブの初回投与から研究完了まで(8年間)
エミシズマブの初回投与から研究完了まで(8年間)
重度の過敏症、アナフィラキシー、アナフィラキシー様事象の発生率
時間枠:エミシズマブの初回投与から研究完了まで(8年間)
エミシズマブの初回投与から研究完了まで(8年間)
研究薬の中止につながる有害事象の発生率
時間枠:エミシズマブの初回投与から研究完了まで(8年間)
エミシズマブの初回投与から研究完了まで(8年間)
脈拍数のベースラインからの時間の経過に伴う変化
時間枠:ベースライン、1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49、53週、および7年間の追跡期間中は毎年修了までの期間(最長8年)
ベースライン、1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49、53週、および7年間の追跡期間中は毎年修了までの期間(最長8年)
呼吸数のベースラインからの時間の経過に伴う変化
時間枠:ベースライン、1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49、53週、および7年間の追跡期間中は毎年修了までの期間(最長8年)
ベースライン、1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49、53週、および7年間の追跡期間中は毎年修了までの期間(最長8年)
体温のベースラインからの時間の経過に伴う変化
時間枠:ベースライン、1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49、53週、および7年間の追跡期間中は毎年修了までの期間(最長8年)
ベースライン、1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49、53週、および7年間の追跡期間中は毎年修了までの期間(最長8年)
最高血圧のベースラインからの経時的変化
時間枠:ベースライン、1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49、53週、および7年間の追跡期間中は毎年修了までの期間(最長8年)
ベースライン、1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49、53週、および7年間の追跡期間中は毎年修了までの期間(最長8年)
拡張期血圧のベースラインからの経時的変化
時間枠:ベースライン、1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49、53週、および7年間の追跡期間中は毎年修了までの期間(最長8年)
ベースライン、1、2、3、4、5、7、9、13、17、21、25、29、33、37、41、45、49、53週、および7年間の追跡期間中は毎年修了までの期間(最長8年)
Number of Participants According to Hematology and Serum Chemistry Laboratory Test Result Shifts From Baseline WHO Grade to the Highest WHO Grade Post-Baseline
時間枠:Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53

Laboratory parameters for hematology and blood chemistry were measured at baseline and over time, and the values were compared with a standard reference range. Values outside the standard reference range were considered laboratory abnormalities and graded according to the World Health Organization (WHO) toxicity grading scale, ranging from lowest (Grade 1) to greatest (Grade 4) deviation from standard in the direction indicated for the abnormality (i.e., below (Low) or above (High) the reference range; 'Not Low' and 'Not High' indicate values within the reference range). Participants were categorized according to their laboratory test result shift from baseline WHO grade to highest WHO grade at any point post-baseline (up to Week 53) for each parameter. 'Missing' indicates that the test result was not available.

Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53
Incidence of De Novo Development of Factor VIII Inhibitors
時間枠:As clinically indicated from baseline until study completion (up to 8 years)

As per the protocol, after any 3 exposure days to FVIII or a block of FVIII exposure days (e.g., a block is defined as a minimum of two consecutive doses of FVIII) administered for treatment of a bleed, a surgical procedure, or other (e.g., preventative doses before activity), one plasma sample for anti-FVIII antibodies (for centralized analysis) had to be collected 14 days after the final dose of FVIII administered.

As clinically indicated from baseline until study completion (up to 8 years)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Clinical Trials、Hoffmann-La Roche

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年2月4日

一次修了 (実際)

2023年5月22日

研究の完了 (推定)

2030年5月18日

試験登録日

最初に提出

2020年6月11日

QC基準を満たした最初の提出物

2020年6月11日

最初の投稿 (実際)

2020年6月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月1日

QC基準を満たした最後の更新が送信されました

2026年9月30日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • MO41787
  • 2020-001733-12 (EudraCT番号)
  • 2023-505964-13-00 (レジストリ識別子:EU CT Number)
  • 2023 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。